Plain-English translation of NCT04988945 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a combination approach for people with advanced liver cancer that cannot currently be surgically removed. Researchers are combining two existing treatments—focused radiation therapy and two immune-boosting medications called and —to see if together they can shrink the tumors enough to make surgery possible. The goal is to give patients a chance at a cure that they wouldn't otherwise have.
Currently, most patients diagnosed with advanced liver cancer cannot have surgery to remove it, and standard treatments like chemotherapy injected into blood vessels rarely cure the disease. Researchers believe that combining focused radiation with immune-boosting medications may be more powerful than existing treatments alone and could potentially shrink tumors enough to allow surgery—the only truly curative option.
You likely qualify if…
You likely don't qualify if…
You would first receive a specialized focused radiation treatment called SBRT along with chemotherapy delivered through blood vessels (TACE), designed to shrink your tumors. Then you would begin receiving the two immune-boosting medications intravenously (through an IV), with treatments every 4 weeks. You would need regular clinic visits for imaging scans, blood tests, and medical evaluations to monitor how well the treatment is working and to watch for side effects, continuing until your tumor shrinks enough for surgery or until it stops responding.
AI-generated summary from trial data · Jul 21, 2026 · Not medical advice
Hong Kong